Loading...

PDSB PDS BIOTECHNOLOGY CORP Capital Structure Changes 8-K Filing

PDS

PDSB

PDS BIOTECHNOLOGY CORP

(PDSB)

2024 8-K

Show Summary

Summary

Financial Update

Market Expansion

Compensatory Arrangements o...

Research Announcement

Clinical Trials

Financial Statements

New Product Launches

Debt-Equity Swaps

Securities Offering

Clinical Trial Update

Public Offering

Public Offering

Clinical Trial Update

Earnings Reports

Quantitative Data

Annual Meeting and Amendmen...

Filing Letter with Quantita...

Merger of Equals

Earnings Reports

Quantitative Data

Merger of Equals

Quantitative Data

Quantitative Data Mentioned

Filing Letter with Quantita...

Quantitative Data Mentioned

Quantitative Data

Quantitative Data

Quantitative Data

Quantitative Data

Annual Meeting Approval

Quantitative Data

Quantitative Data Mentioned

Quantitative Data

Quantitative Data Mentioned

Quantitative Data Mentioned

Quantitative Data

Quantitative Data

Quantitative Data

Quantitative Data

Quantitative Data

Quantitative Data Mentioned

Quantitative Data

External Links:

PDS Biotechnology Corp has entered into a new sales agreement allowing it to sell up to $50 million of its common stock through B. Riley Securities and H.C. Wainwright & Co. The agreement replaces a previous one and includes a 3% commission for the agents on sales made.

AI Assistant

PDS BIOTECHNOLOGY CORP

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.